OGN News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

OG

Mkt Cap

$3.61B

Volume

2.41M

Next Earnings

November 9th

Loading chart

OG

OGNOrganon & Co.

OGN

Pay with—

Available Balance0.00

OG

Mkt Cap

$3.61B

Volume

2.41M

Next Earnings

November 9th

Chart Financials Earnings News About Dividends Insider Filings

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to KnowOrganon (OGN) is receiving significant investor attention. The pharmaceutical company shows declining earnings estimates for the current fiscal year (-7.9%) but modest growth expected for next year (+7%). Revenue growth remains flat to slightly negative. With a Zacks Rank #3 (Hold) rating and a Grade A valuation score indicating the stock trades at a discount to peers, the company is expected to perform in line with the broader market in the near term.Zacks Investment Research · Oct 14, 2026

Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending StockOrganon (OGN), a pharmaceutical company, is being closely watched by investors. The stock has underperformed the S&P 500 over the past month (-0.4% vs +0.6%). Earnings estimates remain unchanged with expected EPS of $0.91 for the current quarter (down 9.9% YoY) and $3.37 for the fiscal year (down 7.9% YoY). Revenue is expected to decline slightly. The company received a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market. However, it is trading at a discount to peers based on valuation metrics.Zacks Investment Research · Oct 2, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)Brodsky & Smith law firm has announced investigations into multiple merger transactions, including Apogee Therapeutics (acquired by AbbVie for $135.11/share), Roku (acquired by Fox for $160/share), TruBridge (acquired by Inventurus for $26.25/share), and Organon (acquired by Sun Pharmaceutical for $14/share). The investigations focus on whether the respective boards breached fiduciary duties by failing to conduct fair processes and whether deal consideration provides fair value to shareholders.GlobeNewswire Inc. · Jun 22, 2026

Halper Sadeh LLC is Investigating Whether LPRO, NUVL, OGN, SUNE are Obtaining Fair Deals for their ShareholdersInvestor rights law firm Halper Sadeh LLC is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.GlobeNewswire Inc. · Jun 17, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG), Organon & Co. (NYSE – OGN)Brodsky & Smith law firm is investigating four merger transactions to determine whether company boards breached fiduciary duties by failing to conduct fair processes and provide fair value to shareholders. The investigations involve Simulations Plus ($18.50/share), Roku ($160.00/share), TruBridge ($26.25/share), and Organon ($14.00/share).GlobeNewswire Inc. · Jun 16, 2026

Halper Sadeh LLC is Investigating Whether NUVL, SUNE, OGN, TMHC are Obtaining Fair Deals for their ShareholdersInvestor rights law firm Halper Sadeh LLC is investigating four major corporate transactions for potential securities law violations and breaches of fiduciary duties. The investigations cover Nuvalent's $124/share sale to GSK, SUNation Energy's merger with Suniva, Organon's $14/share sale to Sun Pharmaceutical, and Taylor Morrison's $72.50/share sale to Berkshire Hathaway. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.GlobeNewswire Inc. · Jun 10, 2026

Hanmi Pharmaceutical se asocia con Organon para exportar terapias combinadas al Sudeste AsiáticoHanmi Pharmaceutical has signed a supply agreement with Organon to export three combination medicines in cardiovascular and respiratory therapeutic areas to Malaysia and the Philippines. Organon will handle marketing, distribution, and sales in these markets, with potential for expansion in the medium to long term.GlobeNewswire Inc. · May 22, 2026

Hanmi Pharmaceutical Faz Parceria com a Organon para Exportação de Terapias de Combinação para o Sudeste AsiáticoHanmi Pharmaceutical has signed a supply agreement with Organon to export three combination medicines for cardiovascular and respiratory therapeutic areas to Malaysia and the Philippines. Organon will handle marketing, distribution, and sales in these markets, with potential for medium to long-term expansion. The partnership leverages the growing demand for combination therapies in Southeast Asia's rapidly expanding pharmaceutical market.GlobeNewswire Inc. · May 22, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Veris Residential, Inc. (NYSE – VRE), XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX)Brodsky & Smith law firm announced investigations into four merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and pay fair value to shareholders. The investigations involve Veris Residential ($19.00/share), XOMA Royalty ($39.00/share), Organon ($14.00/share), and RE/MAX Holdings ($13.80/share or stock election).GlobeNewswire Inc. · May 14, 2026

Halper Sadeh LLC is Investigating Whether HLX, OGN, XOMA, RMAX are Obtaining Fair Deals for their ShareholdersHalper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to proposed mergers and acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be prioritized over ordinary shareholder interests.GlobeNewswire Inc. · May 7, 2026

to start trading

OG

OGNOrganon & Co.

OGN

Pay with—

Available Balance0.00

Your PositionYou don't own any OGN yet.

Related Tickers

Earnings

Dividends

Last · Aug 14Quarterly

Amount$0.0200

Yield0.58%

Annual$0.0800